论文信息 - LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma - 字舞流文

LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma

M. Kudo | T. Yau | R. Finn | B. Sangro | S. Choo | J. Neely | J. Harding | Joong-Won Park | L. Wyrwicz | A. Cheng | E. Schott | P. Mathurin | M. Tschaika | O. Rosmorduc | P. Merle | J. Edeline | K. Han | D. Begic | G. Chen | R. Kelley